The white blood cell as a risk factor for thrombotic vascular disease

Belch, J. J. F.

doi:10.1177/1358836x9000100208

Cited by 9 publications

(3 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An elevated leukocyte count prior to initiation of chemotherapy was identified as 1 of 5 clinical factors predictive of increased risk for venous thromboembolism [15,16]. There is also evidence of a relationship between an elevated leukocyte count and arterial thrombosis, including myocardial infarction [17,18]. Cancer patients with leukocytosis receiving systemic chemotherapy have a poor prognosis [16].…”

Section: Discussionmentioning

confidence: 99%

“…Leukocytes mediate cell damage and may have a broader and earlier role in the acute injury process. Leukocytosis may be a marker of an underlying process such as an aggressive cancer, major comorbid illness or active inflammation or may directly contribute to both arterial and venous thrombus formation [15,16,17,18,19]. White blood cells are large cells and by aggregating together they can slow down blood flow in the microcirculation.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Chemotherapy-Related Thrombocytosis: Does It Increase the Risk of Thromboembolism?

et al. 2012

View full text Add to dashboard Cite

Objectives: Chemotherapy increases the risk of thromboembolism in patients with cancer. Although thrombocytopenia is a known side effect of chemotherapy, reactive thrombocytosis related to chemotherapy is uncommonly reported. The present study aimed to determine the incidence of gemcitabine-related thrombocytosis and the associated risk of thromboembolism. Methods: Medical records of 250 consecutive patients with a malignant disease who received gemcitabine-based therapy were reviewed. A multivariate analysis was done to determine factors associated with thromboembolism. Results: A total of 220 eligible patients with a median age of 63 years (range 26–83) were identified. Of these 220 patients, 95% had advanced malignancy and 59% had received prior chemotherapy. A total of 69% of patients received a platinum combination. In all, 46% patients experienced thrombocytosis following chemotherapy, with a median platelet count of 632 × 10⁹/l (range 457–1,385). Twenty-three of the 220 patients experienced a vascular event within 6 weeks of treatment. Eleven patients with thrombocytosis experienced a vascular event compared with 10 patients without thrombocytosis (not significant). On multivariate analysis, leukocytosis (odds ratio 5.8, 95% confidence interval 2.1–15.8) and comorbid illnesses (odds ratio 4.1, 95% confidence interval 1.4–12.6) were correlated with thromboembolism. Conclusions: Although gemcitabine-based therapy has been associated with an increased incidence of thrombocytosis, it does not increase the risk of thromboembolism in cancer patients. Leukocytosis and comorbid illnesses do increase the risk of thromboembolism.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Chemotherapy-Related Thrombocytosis: Does It Increase the Risk of Thromboembolism?

et al. 2012

View full text Add to dashboard Cite

show abstract

“…The sources of these circulating enzymes remain to be defined; however, circulating leucocytes or platelets or both represent likely candidates for mediators of the observed increases. Poor glycaemic control is known to profoundly disturb the functions of circulating leucocytes [18] and also leads to abnormal physical properties such as decreased surface charge [19], tending to increase leucocyte interaction with other circulating ceils and with vascular endothelium [20]. Leucocyte activation, which would occur under these circumstances, is reportedly accompanied by increased synthesis of fl-D-glucuronidase [21] and some other lysosomal enzymes [2,22].…”

Section: Discussionmentioning

confidence: 99%

Increases in plasma lysosomal enzymes in Type 1 (insulin-dependent) diabetes mellitus: relationship to diabetic complications and glycaemic control

et al. 1992

View full text Add to dashboard Cite

Lysosomal enzymes degrade membrane glycoconjugates, and increased circulating enzyme activity may be an important mechanism in the pathogenesis of diabetic microangiopathy. We have assayed a profile of seven lysosomal enzyme activities (nmol.h-1.ml-1) in platelet-free plasma from 54 Type 1 (insulin-dependent) diabetic subjects (median age 31 years) and 42 matched normal control subjects. A significant increase in median (interquartile range) enzyme activity was measured in diabetic compared to control subjects for beta-D-glucuronidase, 121 (97.7-171) vs 88.8 (62.8-113), p less than 0.001; beta-D-Nacetylglucosaminidase, 693 (568-799) vs 568 (462-686), p less than 0.001; alpha-D-mannosidase, 23.8 (16.7-28.9) vs 14.5 (10.1-20.0), p less than 0.001; and beta-D-galactosidase, 6.94 (6.11-9.99) vs 6.66 (4.78-8.33), p less than 0.04. In contrast, alpha-L-fucosidase, alpha-D-galactosidase and beta-D-mannosidase activities were similar in diabetic and control subjects. None of the enzyme activities differed significantly (p less than 0.05) between 24 diabetic patients with clinical complications and 30 complication-free diabetic patients with similar glycaemic control which does not support the hypothesis that enzyme increases in diabetes arise simply by leakage from damaged tissues. In the diabetic subjects HbA1, median (interquartile range) 9.10 (7.40-10.60), was significantly related to beta-D-glucuronidase (rs = 0.56, p less than 0.001) and beta-D-Nacetylglucosaminidase (rs = 0.55, p less than 0.001). We have therefore demonstrated in diabetic subjects an increase in certain lysosomal glycosidases, that correlates with glycaemic control.(ABSTRACT TRUNCATED AT 250 WORDS)

show abstract

Neutrophils may contribute to the morbidity and mortality of claudicants

Hickman

McCollum

Belch

1994

Journal of British Surgery

View full text Add to dashboard Cite

Peripheral arterial occlusive disease is a common cause of morbidity in middle-aged men; 5 per cent of those aged over 50 years suffer from intermittent claudication. While claudication itself is not fatal, claudicants have a mortality rate approximately three times that of non-claudicating men of the same age, mainly from cardiovascular disease. This review examines the evidence for involvement of the neutrophil in this increased mortality and describes the possible pathogenesis. It also discusses how treatment of claudication may modify neutrophil behaviour, reducing subsequent mortality and morbidity rates.

show abstract

The white blood cell as a risk factor for thrombotic vascular disease

Cited by 9 publications

References 56 publications

Chemotherapy-Related Thrombocytosis: Does It Increase the Risk of Thromboembolism?

Chemotherapy-Related Thrombocytosis: Does It Increase the Risk of Thromboembolism?

Increases in plasma lysosomal enzymes in Type 1 (insulin-dependent) diabetes mellitus: relationship to diabetic complications and glycaemic control

Neutrophils may contribute to the morbidity and mortality of claudicants

Contact Info

Product

Resources

About